Bevacizumab for Recurrent Hemangioendothelioma

Acta Oncologica - United Kingdom
doi 10.3109/0284186x.2010.498829
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Addition of Lomustine for Bevacizumab-Refractory Recurrent Glioblastoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2014English

Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

2012English

Bevacizumab and Chemotherapy for Recurrent Glioblastoma: A Single-Institution Experience

Neurology
Neurology
2009English

Sustained Focal Antitumor Activity of Bevacizumab in Recurrent Glioblastoma

Neurology
Neurology
2014English

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2009English

Pseudomyogenic Hemangioendothelioma

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2019English

Efficacy and Safety of Oxaliplatin, Bevacizumab and Oral S-1 for Advanced Recurrent Colorectal Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2016English

Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2016English

Erratum To: Single-Agent Bevacizumab Is an Effective Treatment in Recurrent Glioblastoma

Medical Oncology
MedicineCancer ResearchOncologyHematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy